Find alpha where nobody's looking

AMSS surged +116% after Good Twin Wine was announced as the #1 organic non-alcoholic wine brand in the U.S. — a category so niche it's essentially meaningless. The stock direct listed at $17 on May 20, crashed to $3.50 in a week, and is now bouncing on a press release. Revenue has collapsed 47% from $33.5M to $17.8M over two years. Gross margins fell from 32% to 21%. The company loses $14.6M annually and just filed an 8-K for a $6.99M Series C convertible preferred raise — dilutive. The non-alc beverage trend is real, but AMASS is a value-destroying brand aggregator with deteriorating fundamentals. Avoid.

CODX surged +30% on the CoMira Saudi JV moving to execution phase and an ESCMID presentation. But Q1 2026 revenue was $146,000. That's not a typo. The company lost $9.1M in the quarter on $146K in revenue — a 62,000% loss-to-revenue ratio. Revenue has collapsed 99.8% from its $298M FY2021 COVID peak. The Saudi manufacturing JV is real but years from generating meaningful revenue. Co-Dx PCR platform needs FDA submission, clinical validation, and commercial scaling — all uncertain. At ~$52M market cap for a company with $720K TTM revenue, CODX is massively overvalued. Avoid.

MetaVia surged +42% after presenting DA-1726 (a GLP-1/glucagon dual agonist for obesity) and vanoglipel (GPR119 agonist for diabetes) data at ADA 2026. Fein reiterated Buy with a $20 PT. The GLP-1 market is a $100B+ opportunity and DA-1726's once-weekly oxyntomodulin analog is differentiated from Wegovy/Zepbound. But: zero revenue, $13.7M annual loss, 139% share dilution, Phase 1 only, and a stock that traded at $1.4M/share pre-split. The $20 PT requires DA-1726 to succeed in Phase 2/3 and compete against Eli Lilly and Novo Nordisk. At $8M market cap, the option value is cheap but the binary risk is extreme. Speculative Buy for risk capital only.